Product Description
Format: PDF
Number of Pages: 166
The aim of this report is to provide information about vaccines in development for unconventional indications and non-infectious diseases. Further focus will be placed on sophisticated antigen(s)-specific vaccines where induced polyclonal antibodies are claimed to be the main mode of action. The scope of this report does not include vaccines against microorganisms which are used for non-infectious diseases (e.g. cancer vaccines targeting HPV). Also, the term “vaccine” as used in this report does not mean a monoclonal antibody (mAb) or immunoglobulin (IgGs) infusion.
Rather than explaining the background behind immune reactions a comparative overview will be made of active candidates with details on indications, targets, stage of development, technologies and the companies supporting them. Target product profiles will be provided for the most advanced candidates and details on single vaccines will also be provided for other vaccines in active development.
Target product profiles contain (when available): Name and alternative names of a candidate vaccine, Target, Indication, Originator company, Licensee company, Stage of development, Start, Expected/Actual year of finishing, Web site of the developing company, Drug schedule, Route of administration, Dosage, Results from current/previous development, Clinical trial ID, Technology/Vaccine composition, Results link, MoA, Special designation and Notes on the candidate. Target product profiles on Phase I and Preclinical candidates contain (when available): Target, Indication, Originator company, Licensee company, Stage of development, Start, Expected/Actual year of finishing, Web site of the developing company, Clinical trial ID (for Phase I candidates), Technology/Vaccine composition and Notes.
Most of the vaccines here will be synthetic vaccines generally composed of a synthetic B-cell epitope(s), usually coupled to a carrier in order to introduce T-cell epitopes necessary for inducing a correct and complete immune response and an adjuvant for amplifying immune response. This view is of course very simplified and details about vaccine composition will be discussed for the individual vaccines.
“Pure” T-cell vaccines (where the main mode of action is mediated by T lymphocytes) have not been included. However, some of the vaccines included report both modes of action equally and the importance of each is still to be elucidated.
Reference is also made to “Selected special antibody-inducing vaccines” which are interesting from a technological and conceptual point of view although they do not strictly fall into above mentioned scope of this review. There is a potentialthat these vaccines or the technologies behind them will be used more generally in the future, once they have been further elucidated, defined and developed.
The scope of the current report includes more than 100 active vaccine projects. Basic information is also given on dozens of stopped projects. A single vaccine project means a vaccine used for a single indication. Some vaccines (same formulation) are developed for more than one indication. Also, when a new formulation is disclosed, this is also counted as a new vaccine.
If you request a Sample, please contact us directly: info@martinalutter.com
Content:
1. Aim and Scope 2
2. Introduction 3
3. Indications 4
4. Targets 12
5. Most advanced vaccines (Phase III- Phase I/II) 14
5.1. Overview 14
5.2. Target product profiles (TPPs) 18
6. Phase I vaccines 65
6.1. Overview 65
6.2. Details on Phase I vaccines 69
7. Preclinical candidates 101
7.1. Overview 101
7.2. Details on vaccines in preclinical development 106
8. Most active players in the field 155
9. Stopped vaccines 155
10. Summary 158
11. Disclaimer 160
12. Sources 160
13. Feedback form 160
14. Abbreviations, Terms 161
15. List of tables 163
16. List of Figures 165
17. About Martina Lutter s.r.o 166
List of Tables:
Table 1 List of vaccines for cancer indications 4
Table 2 List of vaccines for neurodegenerative diseases 7
Table 3 List of vaccines for allergies 8
Table 4 List of vaccines for addictions 9
Table 5 List of vaccines for cardiovascular diseases 10
Table 6 List of vaccines for autoimmune disorders 11
Table 7 List of most frequent targets used for vaccines development 13
Table 8 TPP of Vaccine 1 18
Table 9 TPP of Vaccine 2 20
Table 10 TPP of Vaccine 3 22
Table 11 TPP of Vaccine 4 24
Table 12 TPP of Vaccine 5 26
Table 13 TPP of Vaccine 6 28
Table 14 TPP of Vaccine 7 30
Table 15 TPP of Vaccine 8 32
Table 16 TPP of Vaccine 9 34
Table 17 TPP of Vaccine 10 36
Table 18 TPP of Vaccine 11 38
Table 19 TPP of Vaccine 12 40
Table 20 TPP of Vaccine 13 41
Table 21 TPP of Vaccine 14 42
Table 22 TPP of Vaccine 15 43
Table 23 TPP of Vaccine 16 45
Table 24 TPP of Vaccine 17 47
Table 25 TPP of Vaccine 18 49
Table 26 TPP of Vaccine 19 50
Table 27 TPP of Vaccine 20 51
Table 28 TPP of Vaccine 21 53
Table 29 TPP of Vaccine 22 55
Table 30 TPP of Vaccine 23 57
Table 31 TPP of Vaccine 24 59
Table 32 TPP of Vaccine 25 61
Table 33 TPP of a recently discontinued vaccine 63
Table 34 List of Phase I vaccines 65
Table 35 TPP of Vaccine 26 69
Table 36 TPP of Vaccine 27 70
Table 37 TPP of Vaccine 28 71
Table 38 TPP of Vaccine 29 72
Table 39 TPP of Vaccine 30 73
Table 40 TPP of Vaccine 31 74
Table 41 TPP of Vaccine 32 75
Table 42 TPP of Vaccine 33 76
Table 43 TPP of Vaccine 34 77
Table 44 TPP of Vaccine 35 78
Table 45 TPP of Vaccine 36 79
Table 46 TPP of Vaccine 37 80
Table 47 TPP of Vaccine 38 81
Table 48 TPP of Vaccine 39 82
Table 49 TPP of Vaccine 40 83
Table 50 TPP of Vaccine 41 84
Table 51 TPP of Vaccine 42 85
Table 52 TPP of Vaccine 43 86
Table 53 TPP of Vaccine 44 87
Table 54 TPP of Vaccine 45 88
Table 55 TPP of Vaccine 46 89
Table 56 TPP of Vaccine 47 90
Table 57 TPP of Vaccine 48 91
Table 58 TPP of Vaccine 49 92
Table 59 TPP of Vaccine 50 93
Table 60 TPP of Vaccine 51 94
Table 61 TPP of Vaccine 52 95
Table 62 TPP of Vaccine 53 96
Table 63 TPP of Vaccine 54 97
Table 64 TPP of Vaccine 55 98
Table 65 TPP of Vaccine 56 99
Table 66 TPP of Vaccine 57 100
Table 67 List of vaccines in preclinical development 101
Table 68 TPP of Vaccine 58 106
Table 69 TPP of Vaccine 59 107
Table 70 TPP of Vaccine 60 108
Table 71 TPP of Vaccine 61 109
Table 72 TPP of Vaccine 62 110
Table 73 TPP of Vaccine 63 111
Table 74 TPP of Vaccine 64 112
Table 75 TPP of Vaccine 65 113
Table 76 TPP of Vaccine 66 114
Table 77 TPP of Vaccine 67 115
Table 78 TPP of Vaccine 68 116
Table 79 TPP of Vaccine 69 117
Table 80 TPP of Vaccine 70 118
Table 81 TPP of Vaccine 71 119
Table 82 TPP of Vaccine 72 120
Table 83 TPP of Vaccine 73 121
Table 84 TPP of Vaccine 74 122
Table 85 TPP of Vaccine 75 123
Table 86 TPP of Vaccine 76 124
Table 87 TPP of Vaccine 77 125
Table 88 TPP of Vaccine 78 126
Table 89 TPP of Vaccine 79 127
Table 90 TPP of Vaccine 80 128
Table 91 TPP of Vaccine 81 129
Table 92 TPP of Vaccine 82 130
Table 93 TPP of Vaccine 83 131
Table 94 TPP of Vaccine 84 132
Table 95 TPP of Vaccine 85 133
Table 96 TPP of Vaccine 86 134
Table 97 TPP of Vaccine 87 135
Table 98 TPP of Vaccine 88 136
Table 99 TPP of Vaccine 89 137
Table 100 TPP of Vaccine 90 138
Table 101 TPP of Vaccine 91 139
Table 102 TPP of Vaccine 92 140
Table 103 TPP of Vaccine 93 141
Table 104 TPP of Vaccine 94 142
Table 105 TPP of Vaccine 95 143
Table 106 TPP of Vaccine 96 144
Table 107 TPP of Vaccine 97 145
Table 108 TPP of Vaccine 98 146
Table 109 TPP of Vaccine 99 147
Table 110 TPP of Vaccine 100 148
Table 111 TPP of Vaccine 101 149
Table 112 TPP of Vaccine 102 150
Table 113 TPP of Vaccine 103 151
Table 114 TPP of Vaccine 104 152
Table 115 TPP of Vaccine 105 153
Table 116 TPP of Vaccine 106 154
Table 117 Selection of stopped vaccines 157
List of Figures:
Figure 1 Overview of active and inactive/unknown status vaccines according to therapeutic area 12
Figure 2 Most advanced vaccines timelines 17
